Verastem Oncology Competitors and Similar CompaniesClear all
Tanvex BioPharma's competitors and similar companies include Novartis and Relay Therapeutics.
 Tanvex BioPharma Tanvex BioPharma (formerly known as Ruenvex Biotech) is a company that manufactures and develops biosimilar and biologic products and drugs. |  Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. |  Relay Therapeutics Relay Therapeutics was founded on the premise that putting protein motion at the heart of drug discovery can dramatically expand therapeutic possibilities. | |
Founding Date | Founding Date 2013 | Founding Date 1996 | Founding Date 2016 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Taipei, TW HQ New Taipei, TW Irvine, US San Diego, US San Diego, US | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations Cambridge, US HQ |
Employees | Employees 13827% decrease | Employees 75,883 | Employees 2724% decrease |
Financial | |||
Revenue (est.) | Revenue (est.) NT$401m (FY, 2025) | Revenue (est.) $56.7b (FY, 2025) | Revenue (est.) $15.4m (FY, 2025) |
Cost of goods | Cost of goods NT$466.3m (FY, 2025) | Cost of goods $8.4b (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit (NT$10.6m) (FY, 2025) | Gross profit $49.8b (FY, 2025) | Gross profit N/A |
Net income | Net income (NT$1.5b) (FY, 2025) | Net income $14b (FY, 2025) | Net income ($276.5m) (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised $ 346.9m | Total funding raised $ 6.5m | Total funding raised $ 520m |
For sources of this data, please see the company profile
View Company Profiles
Novartis
HQ
Basel, CH
Employees
75,883
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
View companyRelay Therapeutics
HQ
Cambridge, US
Employees
272↓ 4% decrease
Relay Therapeutics was founded on the premise that putting protein motion at the heart of drug discovery can dramatically expand therapeutic possibilities.
View company